• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis builds market presence
Share
News

ProAxsis builds market presence

June 20, 2016
-
Posted by Webmaster

ProAxsis (www.proaxsis.com) is undertaking business development activities with Invest Northern Ireland support. Speaking about the plans, Dr David Ribeiro, CEO of ProAxsis, said: “This funding will allow us to complete further commercial activities concerning the development of our point-of-care test, for detecting neutrophil elastase as a biomarker of infection and inflammation in patients with chronic respiratory diseases such as COPD and cystic fibrosis. Invest NI is a fantastic supporter of innovative companies based in Northern Ireland, and we’re very grateful for their continuing support.”
Invest NI has offered ProAxsis £48,000 to support its market development activities.

Ian Murphy, Invest NI’s Director of Growth and Scaling, added: “ProAxsis is a highly innovative University spinout focused on growing its customer base outside Northern Ireland. Invest NI’s support is helping the business gain greater insight into the potential business opportunities for its medical technology so that it can reach its export potential.”

Any queries concerning ProAxsis’ Immunoassays for measuring active neutrophil elastase and active Cathepsin G, or any other aspects of the company’s proprietary ProteaseTag® technology, can be directed to info@77.104.171.207. For further information about Invest Northern Ireland, please visit www.investni.com

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

June 20, 2016

Related News

Other posts that you should not miss.
NEATstik®, News

ProAxsis registers European CE Mark for first neutrophil elastase point-of-care test

September 4, 2017
-
Posted by Webmaster

ProAxsis Ltd today announces that the company has completed the development process for NEATstik®, a novel point-of-care …

Read More
September 4, 2017
Posted by Webmaster
Conferences, Neutrophil Elastase Immunoassay, News, ProteaseTag®

ProAxsis’ ProteaseTag® NE Immunoassay highlighted at BTS 2016

December 8, 2016
-
Posted by Webmaster

ProAxsis (www.proaxsis.com) was delighted to observe that measuring active neutrophil elastase (NE) by its ProteaseTag® Active NE Immunoassay …

Read More
December 8, 2016
Posted by Webmaster
Announcements, NEATstik®, News

New data demonstrates high potential of NEATstik® as a rapid point-of-care monitoring tool for lung diseases

June 3, 2019
-
Posted by Webmaster

Positive early data from the BRIDGE1 study, a three-year 1000+ patient study in bronchiectasis funded by the …

Read More
June 3, 2019
Posted by Webmaster
← PREVIOUS POST
ProAxsis featured in Business Eye
NEXT POST →
ProAxsis team to attend BIO 2016
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis builds market presence - ProAxsis